Loading
The trial that showed Ph-positive ALL can be treated with a pill plus an immunotherapy and no chemotherapy, with 95% of patients alive at 18 months.
63 patients (median age 54): molecular response 60% after two blinatumomab cycles rising with further cycles; 18-month OS 95%, DFS 88%; only half went to transplant. NEJM 2020. Four-year update: OS ~80%, DFS ~75%, with IKZF1-plus and T315I relapses. Successor trials (GIMEMA ALL2820 with ponatinib) and MD Anderson ponatinib-blinatumomab series extend the chemotherapy-free approach.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
63 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival at 18 months | Dasatinib → blinatumomab | 63 | 95% | - | - | link |
| Disease-free survival at 18 monthsprimary | Dasatinib → blinatumomab | - | 88% | - | - | link |
Shares BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL), Ph-positive ALL, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL), BCR::ABL1 (Philadelphia chromosome).
Shares BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL), Ph-positive ALL, Transplant-free Ph-positive ALL for MRD-negative adults, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL).
Shares Dasatinib, BCR::ABL1 (Philadelphia chromosome), Acute lymphoblastic leukaemia, Small-molecule kinase inhibitors.
Shares GIMEMA, Acute lymphoblastic leukaemia.
Shares Blinatumomab, CD19, Acute lymphoblastic leukaemia.
Shares Dasatinib, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL).
Shares Blinatumomab, CD19, Acute lymphoblastic leukaemia.
Shares Dasatinib, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL), BCR::ABL1 (Philadelphia chromosome), Acute lymphoblastic leukaemia.